Zenas BioPharma (NASDAQ:ZBIO) Director Patricia Allen Purchases 4,160 Shares

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Director Patricia Allen purchased 4,160 shares of the stock in a transaction dated Friday, February 13th. The stock was purchased at an average price of $26.36 per share, with a total value of $109,657.60. Following the completion of the acquisition, the director directly owned 19,860 shares in the company, valued at approximately $523,509.60. The trade was a 26.50% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Zenas BioPharma Stock Performance

ZBIO traded up $0.29 during trading hours on Friday, hitting $26.40. 1,084,522 shares of the stock were exchanged, compared to its average volume of 1,195,034. The stock has a market cap of $1.42 billion, a price-to-earnings ratio of -3.73 and a beta of -1.50. The stock has a 50-day simple moving average of $27.82 and a 200-day simple moving average of $25.51. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. Zenas BioPharma, Inc. has a 12 month low of $6.11 and a 12 month high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last issued its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Hedge Funds Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP increased its position in Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the period. Russell Investments Group Ltd. acquired a new position in Zenas BioPharma during the 3rd quarter worth $30,000. GF Fund Management CO. LTD. bought a new position in shares of Zenas BioPharma in the fourth quarter worth $38,000. BNP Paribas Financial Markets increased its holdings in shares of Zenas BioPharma by 120.0% during the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after purchasing an additional 1,716 shares during the period. Finally, CWM LLC increased its holdings in shares of Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock valued at $79,000 after purchasing an additional 709 shares during the period.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ZBIO. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 target price on shares of Zenas BioPharma in a report on Tuesday, January 6th. Wall Street Zen cut Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th. Morgan Stanley downgraded Zenas BioPharma from an “overweight” rating to an “equal weight” rating and lowered their price objective for the stock from $37.00 to $19.00 in a research note on Monday, January 5th. Finally, Citigroup increased their target price on Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Zenas BioPharma currently has an average rating of “Moderate Buy” and a consensus price target of $43.14.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.